Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Development of a novel ROR1 peptide-based cancer vaccine

Jan. 9, 2014

Committee recommends stopping Imbruvica study based on significant survival improvement

Jan. 8, 2014

Generex Biotechnology confirms database lock for AE-37 breast cancer vaccine trial

Jan. 8, 2014

Vaccination with ImMucin leads to promising clinical response in phase I/II trials

Jan. 8, 2014

FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC

Jan. 7, 2014

Sanofi presents phase II data for SAR-3419 and rituximab combination in B-cell lymphoma

Jan. 3, 2014

Heat Biologics opens enrollment in phase I/II study of HS-410

Jan. 2, 2014

Peregrine Pharmaceuticals begins phase III trial of bavituximab

Jan. 2, 2014

OncoTherapy Science stops phase III study of C-01 for pancreatic cancer

Dec. 27, 2013

NewLink Genetics begins phase I trial of HyperAcute Renal

Dec. 27, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...